Abiopharma

🔍 Maheshwari Anshul (Executive)

Company: SI-BONE, Inc. (SIBN)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Sold 5,747 shares of Common Stock at $19.55 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: false | shares_owned_after: 246,148.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 11,228 shares of Common Stock at $20.02 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 234,920.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4

Footnotes:

• F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated December 17, 2025.
• F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $19.50 to $19.67, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
• F3: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.05, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
• F4: Includes 167,604 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.